Compounds > 4-[(4-methylphenyl)thio]-2-thieno[2,3-c]pyridinecarboxamide
Page last updated: 2024-12-11

4-[(4-methylphenyl)thio]-2-thieno[2,3-c]pyridinecarboxamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID9839311
CHEMBL ID267678
CHEBI ID114180
SCHEMBL ID7057661

Synonyms (45)

Synonym
HMS3269O07
BRD-K77627880-001-01-6
NCGC00167761-01
CHEBI:114180
NCGC00167761-02
CHEMBL267678 ,
bdbm50098512
4-p-tolylsulfanyl-thieno[2,3-c]pyridine-2-carboxylic acid amide
4-(P-TOLYLTHIO)THIENO[2,3-C]PYRIDINE-2-CARBOXAMIDE ,
4-[(4-methylphenyl)thio]thieno[2,3-c]pyridine-2-carboxamide
a 205804
251992-66-2
S2885
thieno(2,3-c)pyridine-2-carboxamide, 4-((4-methylphenyl)thio)-
4-((4-methylphenyl)thio)thieno(2,3-c)pyridine-2-carboxamide
unii-tp7tb1sszd
a-205804
tp7tb1sszd ,
T3498
SCHEMBL7057661
AC-33049
AKOS024457147
Q27195214
DTXSID80179864
a205804
HMS3651P04
4-[(4-methylphenyl)sulfanyl]thieno[2,3-c]pyridine-2-carboxamide
AS-71317
thieno[2,3-c]pyridine-2-carboxamide, 4-[(4-methylphenyl)thio]-
J-015866
NCGC00167761-04
SW219899-1
BCP06441
FT-0750798
HMS3677F09
mfcd09038566
HMS3413F09
CCG-267472
EX-A1788
D83118
A919378
HY-100226
CS-0018356
4-(4-methylphenyl)sulfanylthieno[2,3-c]pyridine-2-carboxamide
BKA99266

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)		0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
aryl sulfideAny organic sulfide in which the sulfur is attached to at least one aromatic group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (7)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
RAR-related orphan receptor alphaMus musculus (house mouse)Potency0.10220.16208.818718.1754AID489039
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency0.26720.00798.23321,122.0200AID2551; AID489036; AID489037
DNA polymerase kappa isoform 1Homo sapiens (human)Potency23.77810.031622.3146100.0000AID588579
hormone receptor 3, isoform ADrosophila melanogaster (fruit fly)Potency0.10220.10222.77858.1186AID489038
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Intercellular adhesion molecule 1Homo sapiens (human)IC50 (µMol)11.01000.00301.212210.0000AID91867; AID91868; AID91870; AID91872; AID91874
E-selectinHomo sapiens (human)IC50 (µMol)10.01000.02002.21336.6000AID202422; AID202423; AID202425; AID202427
Vascular cell adhesion protein 1Homo sapiens (human)IC50 (µMol)19.25006.00006.50007.0000AID216483; AID216485; AID216489; AID216491
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (54)

Processvia Protein(s)Taxonomy
regulation of leukocyte mediated cytotoxicityIntercellular adhesion molecule 1Homo sapiens (human)
T cell activation via T cell receptor contact with antigen bound to MHC molecule on antigen presenting cellIntercellular adhesion molecule 1Homo sapiens (human)
T cell antigen processing and presentationIntercellular adhesion molecule 1Homo sapiens (human)
positive regulation of cellular extravasationIntercellular adhesion molecule 1Homo sapiens (human)
cell adhesionIntercellular adhesion molecule 1Homo sapiens (human)
heterophilic cell-cell adhesion via plasma membrane cell adhesion moleculesIntercellular adhesion molecule 1Homo sapiens (human)
leukocyte cell-cell adhesionIntercellular adhesion molecule 1Homo sapiens (human)
membrane to membrane dockingIntercellular adhesion molecule 1Homo sapiens (human)
cell adhesion mediated by integrinIntercellular adhesion molecule 1Homo sapiens (human)
adhesion of symbiont to hostIntercellular adhesion molecule 1Homo sapiens (human)
symbiont entry into host cellIntercellular adhesion molecule 1Homo sapiens (human)
receptor-mediated virion attachment to host cellIntercellular adhesion molecule 1Homo sapiens (human)
leukocyte migrationIntercellular adhesion molecule 1Homo sapiens (human)
establishment of endothelial barrierIntercellular adhesion molecule 1Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeIntercellular adhesion molecule 1Homo sapiens (human)
cellular response to glucose stimulusIntercellular adhesion molecule 1Homo sapiens (human)
T cell extravasationIntercellular adhesion molecule 1Homo sapiens (human)
regulation of ruffle assemblyIntercellular adhesion molecule 1Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway via death domain receptorsIntercellular adhesion molecule 1Homo sapiens (human)
cellular response to amyloid-betaIntercellular adhesion molecule 1Homo sapiens (human)
cellular response to leukemia inhibitory factorIntercellular adhesion molecule 1Homo sapiens (human)
negative regulation of endothelial cell apoptotic processIntercellular adhesion molecule 1Homo sapiens (human)
positive regulation of receptor internalizationE-selectinHomo sapiens (human)
leukocyte migration involved in inflammatory responseE-selectinHomo sapiens (human)
positive regulation of leukocyte migrationE-selectinHomo sapiens (human)
inflammatory responseE-selectinHomo sapiens (human)
heterophilic cell-cell adhesion via plasma membrane cell adhesion moleculesE-selectinHomo sapiens (human)
leukocyte cell-cell adhesionE-selectinHomo sapiens (human)
activation of phospholipase C activityE-selectinHomo sapiens (human)
calcium-mediated signalingE-selectinHomo sapiens (human)
actin filament-based processE-selectinHomo sapiens (human)
response to lipopolysaccharideE-selectinHomo sapiens (human)
response to tumor necrosis factorE-selectinHomo sapiens (human)
regulation of inflammatory responseE-selectinHomo sapiens (human)
leukocyte tethering or rollingE-selectinHomo sapiens (human)
response to interleukin-1E-selectinHomo sapiens (human)
positive regulation of leukocyte tethering or rollingE-selectinHomo sapiens (human)
response to cytokineE-selectinHomo sapiens (human)
response to hypoxiaVascular cell adhesion protein 1Homo sapiens (human)
chronic inflammatory responseVascular cell adhesion protein 1Homo sapiens (human)
inflammatory responseVascular cell adhesion protein 1Homo sapiens (human)
cell adhesionVascular cell adhesion protein 1Homo sapiens (human)
heterophilic cell-cell adhesion via plasma membrane cell adhesion moleculesVascular cell adhesion protein 1Homo sapiens (human)
leukocyte cell-cell adhesionVascular cell adhesion protein 1Homo sapiens (human)
cell-matrix adhesionVascular cell adhesion protein 1Homo sapiens (human)
response to nutrientVascular cell adhesion protein 1Homo sapiens (human)
amine metabolic processVascular cell adhesion protein 1Homo sapiens (human)
response to zinc ionVascular cell adhesion protein 1Homo sapiens (human)
response to ionizing radiationVascular cell adhesion protein 1Homo sapiens (human)
membrane to membrane dockingVascular cell adhesion protein 1Homo sapiens (human)
B cell differentiationVascular cell adhesion protein 1Homo sapiens (human)
response to lipopolysaccharideVascular cell adhesion protein 1Homo sapiens (human)
cell-cell adhesion mediated by integrinVascular cell adhesion protein 1Homo sapiens (human)
heterotypic cell-cell adhesionVascular cell adhesion protein 1Homo sapiens (human)
response to nicotineVascular cell adhesion protein 1Homo sapiens (human)
cellular response to vascular endothelial growth factor stimulusVascular cell adhesion protein 1Homo sapiens (human)
positive regulation of T cell proliferationVascular cell adhesion protein 1Homo sapiens (human)
response to ethanolVascular cell adhesion protein 1Homo sapiens (human)
leukocyte tethering or rollingVascular cell adhesion protein 1Homo sapiens (human)
cell chemotaxisVascular cell adhesion protein 1Homo sapiens (human)
innervationVascular cell adhesion protein 1Homo sapiens (human)
cardiac neuron differentiationVascular cell adhesion protein 1Homo sapiens (human)
cellular response to tumor necrosis factorVascular cell adhesion protein 1Homo sapiens (human)
cellular response to amyloid-betaVascular cell adhesion protein 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (12)

Processvia Protein(s)Taxonomy
virus receptor activityIntercellular adhesion molecule 1Homo sapiens (human)
transmembrane signaling receptor activityIntercellular adhesion molecule 1Homo sapiens (human)
integrin bindingIntercellular adhesion molecule 1Homo sapiens (human)
protein bindingIntercellular adhesion molecule 1Homo sapiens (human)
signaling receptor activityIntercellular adhesion molecule 1Homo sapiens (human)
transmembrane signaling receptor activityE-selectinHomo sapiens (human)
protein bindingE-selectinHomo sapiens (human)
sialic acid bindingE-selectinHomo sapiens (human)
phospholipase bindingE-selectinHomo sapiens (human)
metal ion bindingE-selectinHomo sapiens (human)
oligosaccharide bindingE-selectinHomo sapiens (human)
integrin bindingVascular cell adhesion protein 1Homo sapiens (human)
primary amine oxidase activityVascular cell adhesion protein 1Homo sapiens (human)
cell adhesion molecule bindingVascular cell adhesion protein 1Homo sapiens (human)
cell adhesion mediator activityVascular cell adhesion protein 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (23)

Processvia Protein(s)Taxonomy
immunological synapseIntercellular adhesion molecule 1Homo sapiens (human)
extracellular spaceIntercellular adhesion molecule 1Homo sapiens (human)
plasma membraneIntercellular adhesion molecule 1Homo sapiens (human)
focal adhesionIntercellular adhesion molecule 1Homo sapiens (human)
external side of plasma membraneIntercellular adhesion molecule 1Homo sapiens (human)
cell surfaceIntercellular adhesion molecule 1Homo sapiens (human)
membraneIntercellular adhesion molecule 1Homo sapiens (human)
membrane raftIntercellular adhesion molecule 1Homo sapiens (human)
collagen-containing extracellular matrixIntercellular adhesion molecule 1Homo sapiens (human)
extracellular exosomeIntercellular adhesion molecule 1Homo sapiens (human)
plasma membraneIntercellular adhesion molecule 1Homo sapiens (human)
extracellular spaceE-selectinHomo sapiens (human)
plasma membraneE-selectinHomo sapiens (human)
caveolaE-selectinHomo sapiens (human)
clathrin-coated pitE-selectinHomo sapiens (human)
cortical cytoskeletonE-selectinHomo sapiens (human)
membrane raftE-selectinHomo sapiens (human)
perinuclear region of cytoplasmE-selectinHomo sapiens (human)
external side of plasma membraneE-selectinHomo sapiens (human)
extracellular spaceE-selectinHomo sapiens (human)
plasma membraneVascular cell adhesion protein 1Homo sapiens (human)
podosomeVascular cell adhesion protein 1Homo sapiens (human)
extracellular spaceVascular cell adhesion protein 1Homo sapiens (human)
early endosomeVascular cell adhesion protein 1Homo sapiens (human)
endoplasmic reticulumVascular cell adhesion protein 1Homo sapiens (human)
Golgi apparatusVascular cell adhesion protein 1Homo sapiens (human)
plasma membraneVascular cell adhesion protein 1Homo sapiens (human)
microvillusVascular cell adhesion protein 1Homo sapiens (human)
external side of plasma membraneVascular cell adhesion protein 1Homo sapiens (human)
cell surfaceVascular cell adhesion protein 1Homo sapiens (human)
filopodiumVascular cell adhesion protein 1Homo sapiens (human)
sarcolemmaVascular cell adhesion protein 1Homo sapiens (human)
apical part of cellVascular cell adhesion protein 1Homo sapiens (human)
extracellular exosomeVascular cell adhesion protein 1Homo sapiens (human)
alpha9-beta1 integrin-vascular cell adhesion molecule-1 complexVascular cell adhesion protein 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (29)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID91868In vitro inhibitory potency compared to IL1-beta induced Intercellular adhesion molecule-1 expression in human endothelial cells (ELISA assay)2001Journal of medicinal chemistry, Oct-11, Volume: 44, Issue:21
Selective inhibition of ICAM-1 and E-selectin expression in human endothelial cells. 2. Aryl modifications of 4-(aryloxy)thieno[2,3-c]pyridines with fine-tuning at C-2 carbamides.
AID91874In vitro potency against TNF alpha induced expression of intercellular adhesion molecule-1 on human vascular endothelial cells using CAM ELISA assay2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
Discovery of inhibitors of cell adhesion molecule expression in human endothelial cells. 1. Selective inhibition of ICAM-1 and E-selectin expression.
AID202427In vitro potency against TNF alpha induced expression of Selectin E on human vascular endothelial cells using CAM ELISA assay2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
Discovery of inhibitors of cell adhesion molecule expression in human endothelial cells. 1. Selective inhibition of ICAM-1 and E-selectin expression.
AID91870In vitro inhibitory potency compared to PMA induced Intercellular adhesion molecule-1 expression in human endothelial cells (ELISA assay)2001Journal of medicinal chemistry, Oct-11, Volume: 44, Issue:21
Selective inhibition of ICAM-1 and E-selectin expression in human endothelial cells. 2. Aryl modifications of 4-(aryloxy)thieno[2,3-c]pyridines with fine-tuning at C-2 carbamides.
AID27443Half-life was measured in rat2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
Discovery of inhibitors of cell adhesion molecule expression in human endothelial cells. 1. Selective inhibition of ICAM-1 and E-selectin expression.
AID202438In vitro inhibitory potency compared to PMA induced Selectin E expression in human endothelial cells (ELISA assay) at 1 uM2001Journal of medicinal chemistry, Oct-11, Volume: 44, Issue:21
Selective inhibition of ICAM-1 and E-selectin expression in human endothelial cells. 2. Aryl modifications of 4-(aryloxy)thieno[2,3-c]pyridines with fine-tuning at C-2 carbamides.
AID91872In vitro inhibitory potency compared to TNF-alpha induced Intercellular adhesion molecule-1 expression in human endothelial cells (ELISA assay)2001Journal of medicinal chemistry, Oct-11, Volume: 44, Issue:21
Selective inhibition of ICAM-1 and E-selectin expression in human endothelial cells. 2. Aryl modifications of 4-(aryloxy)thieno[2,3-c]pyridines with fine-tuning at C-2 carbamides.
AID216485In vitro inhibitory potency compared to IL1-beta induced VCAM-1 expression in human endothelial cells (ELISA assay)2001Journal of medicinal chemistry, Oct-11, Volume: 44, Issue:21
Selective inhibition of ICAM-1 and E-selectin expression in human endothelial cells. 2. Aryl modifications of 4-(aryloxy)thieno[2,3-c]pyridines with fine-tuning at C-2 carbamides.
AID91867Inhibition of intercellular adhesion molecule-1 (ICAM1) in human endothelial cells2001Journal of medicinal chemistry, Oct-11, Volume: 44, Issue:21
Selective inhibition of ICAM-1 and E-selectin expression in human endothelial cells. 2. Aryl modifications of 4-(aryloxy)thieno[2,3-c]pyridines with fine-tuning at C-2 carbamides.
AID28664Aqueous solubility was determined at pH 7.42001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
Discovery of inhibitors of cell adhesion molecule expression in human endothelial cells. 1. Selective inhibition of ICAM-1 and E-selectin expression.
AID85320Toxicity in HUVEC cell lysates2001Journal of medicinal chemistry, Oct-11, Volume: 44, Issue:21
Selective inhibition of ICAM-1 and E-selectin expression in human endothelial cells. 2. Aryl modifications of 4-(aryloxy)thieno[2,3-c]pyridines with fine-tuning at C-2 carbamides.
AID29543Maximum time taken to reach mean plasma concentration, measured in rat2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
Discovery of inhibitors of cell adhesion molecule expression in human endothelial cells. 1. Selective inhibition of ICAM-1 and E-selectin expression.
AID202422Inhibition of selectin E in human endothelial cells2001Journal of medicinal chemistry, Oct-11, Volume: 44, Issue:21
Selective inhibition of ICAM-1 and E-selectin expression in human endothelial cells. 2. Aryl modifications of 4-(aryloxy)thieno[2,3-c]pyridines with fine-tuning at C-2 carbamides.
AID202423In vitro inhibitory potency compared to IL1-beta induced Selectin E expression in human endothelial cells (ELISA assay)2001Journal of medicinal chemistry, Oct-11, Volume: 44, Issue:21
Selective inhibition of ICAM-1 and E-selectin expression in human endothelial cells. 2. Aryl modifications of 4-(aryloxy)thieno[2,3-c]pyridines with fine-tuning at C-2 carbamides.
AID84821In vitro cellular toxicity against human umbilical vein endothelial cells (HUVEC) in MTS assay2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
Discovery of inhibitors of cell adhesion molecule expression in human endothelial cells. 1. Selective inhibition of ICAM-1 and E-selectin expression.
AID216491In vitro potency against TNF alpha induced expression of VCAM-1 on human vascular endothelial cells using CAM ELISA assay2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
Discovery of inhibitors of cell adhesion molecule expression in human endothelial cells. 1. Selective inhibition of ICAM-1 and E-selectin expression.
AID28321Mean plasma concentration measured in rat2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
Discovery of inhibitors of cell adhesion molecule expression in human endothelial cells. 1. Selective inhibition of ICAM-1 and E-selectin expression.
AID216489In vitro inhibitory potency compared to TNF-alpha induced VCAM-1 expression in human endothelial cells (ELISA assay)2001Journal of medicinal chemistry, Oct-11, Volume: 44, Issue:21
Selective inhibition of ICAM-1 and E-selectin expression in human endothelial cells. 2. Aryl modifications of 4-(aryloxy)thieno[2,3-c]pyridines with fine-tuning at C-2 carbamides.
AID25712Area under curve against time (0-8 hr) in rat2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
Discovery of inhibitors of cell adhesion molecule expression in human endothelial cells. 1. Selective inhibition of ICAM-1 and E-selectin expression.
AID202425In vitro inhibitory potency compared to TNF-alpha induced Selectin E expression in human endothelial cells (ELISA assay)2001Journal of medicinal chemistry, Oct-11, Volume: 44, Issue:21
Selective inhibition of ICAM-1 and E-selectin expression in human endothelial cells. 2. Aryl modifications of 4-(aryloxy)thieno[2,3-c]pyridines with fine-tuning at C-2 carbamides.
AID216483Inhibition of VCAM-1 in human endothelial cells2001Journal of medicinal chemistry, Oct-11, Volume: 44, Issue:21
Selective inhibition of ICAM-1 and E-selectin expression in human endothelial cells. 2. Aryl modifications of 4-(aryloxy)thieno[2,3-c]pyridines with fine-tuning at C-2 carbamides.
AID216493In vitro inhibitory potency compared to PMA induced VCAM-1 expression in human endothelial cells (ELISA assay)2001Journal of medicinal chemistry, Oct-11, Volume: 44, Issue:21
Selective inhibition of ICAM-1 and E-selectin expression in human endothelial cells. 2. Aryl modifications of 4-(aryloxy)thieno[2,3-c]pyridines with fine-tuning at C-2 carbamides.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (33.33)29.6817
2010's1 (16.67)24.3611
2020's3 (50.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.78

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.78 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.72 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.78)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
ConditionIndicatedRelationship StrengthStudiesTrials
Adjuvant Arthritis
[description not available]		0210
Asthma, Bronchial
[description not available]		0210
Asthma
A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL).		0210
Congenital Zika Syndrome
[description not available]		02.2510
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.2510
Zika Virus Infection
A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.		02.2510